[Form 4] MaxCyte, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Masoud Maher, who serves as President, CEO and a Director of MaxCyte, Inc. (MXCT), reported the purchase of 75,000 shares on 08/13/2025. The Form 4 discloses the shares were bought in multiple transactions at prices ranging from $1.29 to $1.44, with a reported average price of $1.3722. Following these purchases, Mr. Maher’s direct beneficial ownership increased to 175,000 shares. The filing also states he will provide itemized per-price purchase details on request.

Positive

• Insider acquisition: Masoud Maher purchased 75,000 shares, increasing direct ownership to 175,000 shares.
• Transparent pricing: The filing discloses a purchase price range of $1.29–$1.44 and a reported average price of $1.3722.
• Commitment to detail: Reporting person offers to provide per-price purchase breakdowns upon request, enhancing disclosure.

Negative

• None.

Insights

Securities Analyst

TL;DR: CEO purchased 75,000 MXCT shares at an average ~$1.37, raising direct holdings to 175,000 — modest insider buying reported cleanly.

The transaction is coded as purchases (P) reported on a Form 4 and shows a disclosed price range ($1.29–$1.44) with an average of $1.3722. For investors, this is a verifiable insider acquisition but the filing does not show the transaction size relative to outstanding shares, so its market-moving potential is limited by scale. Disclosure includes an undertaking to provide per-price breakdowns, which improves transparency.

Corporate Governance Expert

TL;DR: Reporting and disclosure are complete: purchase details, price range, and undertaking to supply further breakdown are all included.

The Form 4 identifies the reporting person, relationship to the issuer (President, CEO and Director), transaction code and a clear statement of post-transaction beneficial ownership. No derivative transactions were reported. From a governance and compliance perspective, the filing meets Section 16 reporting requirements and offers additional transparency by noting multiple transactions and the price range.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Masoud Maher

(Last) (First) (Middle)

C/O MAXCYTE, INC.

9713 KEY WEST AVENUE, SUITE 400

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAXCYTE, INC. [ MXCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		P		75,000	A	$1.3722(1)	175,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ David Sandoval, Attorney-in-Fact	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Masoud Maher report for MaxCyte (MXCT)?

He reported purchases of 75,000 shares on 08/13/2025, increasing his direct beneficial ownership to 175,000 shares.

At what prices were the MXCT shares purchased?

The shares were bought in multiple transactions at prices ranging from $1.29 to $1.44, with a reported average price of $1.3722.

Does the Form 4 show any derivative transactions for MXCT?

No. Table II for derivative securities contains no reported transactions.

What role does the reporting person hold at MaxCyte (MXCT)?

The reporting person, Masoud Maher, is identified as President and CEO and a Director of the company.

Will more detailed pricing information be available?

Yes. The filing states the reporting person will provide, upon request, full details regarding the number of shares purchased at each separate price within the disclosed range.